Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

Ambrosini, Valentina; Kunikowska, Jolanta; Baudin, Eric; Bodei, Lisa; Bouvier, Catherine; Capdevila, Jaume; Cremonesi, Marta; de Herder, Wouter; Dromain, Clarisse; Falconi, Massimo; Fani, Melpomeni; Fanti, Stefano; Hicks, Rodney; Kabasakal, LEVENT; Kaltsas, Gregory; Lewington, Val; Minozzi, Silvia; Cinquini, Michela; Oberg, Kjell; Oyen, Wim; O'Toole, Dermot; Pavel, Marianne; Ruszniewski, Philippe; Scarpa, Aldo; Strosberg, Jonathan; Sundin, Anders; Taieb, David; Virgolini, Irene; Wild, Damian; Herrmann, Ken; Yao, James

doi:10.1016/j.ejca.2021.01.008

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

Ambrosini V., Kunikowska J., Baudin E., Bodei L., Bouvier C., Capdevila J., ...Daha Fazla

EUROPEAN JOURNAL OF CANCER, cilt.146, ss.56-73, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Derleme
Cilt numarası: 146
Basım Tarihi: 2021
Doi Numarası: 10.1016/j.ejca.2021.01.008
Dergi Adı: EUROPEAN JOURNAL OF CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, CINAHL, EMBASE, Gender Studies Database, MEDLINE, Veterinary Science Database
Sayfa Sayıları: ss.56-73
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Nuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).